AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.

Xue YiAloke SarkarGorkem KismaliBurcu AslanMary AyresLaKesla R IlesMichael J KeatingWilliam G WierdaJames P LongMaria Teresa Sabrina BertilaccioVarsha Gandhi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

AMG-176 is active in inducing CLL cell death while sparing normal blood cells. Combination with low-dose venetoclax was additive or synergistic.

Keyphrases

chronic lymphocytic leukemia
cell death
cell cycle arrest
low dose
induced apoptosis
high dose
pi k akt
robot assisted
cell therapy
oxidative stress
signaling pathway
cell proliferation
mesenchymal stem cells